Status:
COMPLETED
Trial on the Efficacy and Safety of Two Different Glucocorticoid Dose Regimens in Allergic Bronchopulmonary Aspergillosis
Lead Sponsor:
Post Graduate Institute of Medical Education and Research, Chandigarh
Conditions:
Allergic Bronchopulmonary Aspergillosis
Eligibility:
All Genders
Phase:
PHASE2
PHASE3
Brief Summary
Allergic bronchopulmonary aspergillosis (ABPA) is a pulmonary disorder caused by a complex hypersensitivity response to antigens released by the fungus Aspergillus fumigatus. Oral corticosteroids are ...
Eligibility Criteria
Inclusion
- Diagnosis of ABPA
- Presence of all the following three criteria:
- immediate cutaneous hyperreactivity on aspergillus skin test
- elevated total IgE levels \> 1000 IU/mL
- A fumigatus specific IgE levels \> 0.35 kU/L, AND,
- Presence of two of the following criteria:
- presence of serum precipitating antibodies against A fumigatus
- fixed or transient radiographic pulmonary opacities
- absolute eosinophil count \> 1000/µL
- central bronchiectasis on HRCT
Exclusion
- If they have taken glucocorticoids for more than three weeks in the preceding six months
- Failure to give informed consent
- Enrollment in another trial of ABPA
Key Trial Info
Start Date :
April 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2011
Estimated Enrollment :
92 Patients enrolled
Trial Details
Trial ID
NCT00974766
Start Date
April 1 2009
End Date
March 1 2011
Last Update
February 24 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Postgraduate Institute of Medical Education and Research
Chandigarh, Chandigarh, India, 160012